Compare Quantumscape Corp (QS) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Revvity Inc — how do they compare? Quantumscape Corp trades at $5.25 (market cap $3.44B), while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Revvity Inc is far larger — about 4.1× Quantumscape Corp's market cap, and Revvity Inc pays a 0.22% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| QS | RVTY | |
|---|---|---|
Market Cap | $3.44B | $14.18B |
Sector | Consumer Cyclical | Technology |
52-Week High | $18.44 | $130.94 |
52-Week Low | $4.89 | $82.26 |
Enterprise Value | $2.65B | $16.50B |
Dividend Yield | — | 0.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape trades at $5.59, up 2.01% today but near 52-week lows, with a bearish technical signal from moving averages. The company is pre-revenue, reporting a net loss of $435.05M in 2025, negative ROE of -39.08%, and cash burn from operations. Recent news highlights insider sales and delayed commercialization timelines, with solid-state battery production not expected until 2029.
Outlook remains speculative with high execution risk; analyst consensus is cautious (0% buy, 73% hold, 27% sell). Investment hinges on successful battery commercialization by 2029, but competition and funding needs pose significant threats to shareholder value amid persistent losses.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
